SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Enanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2M

Enanta reported FY2026 revenue of $63.0M versus $65.3M in FY2025 and a net loss of $68.2M, or $2.35 per diluted share, versus $81.9M, or $3.84, in FY2025. Cash and marketable securities were $194.5M at September 30, 2026; the company expects funding into fiscal 2029.Material DetailsContext by AI An…

ENTA

Related stories